CATX
Income statement / Annual
Last year (2023), Perspective Therapeutics, Inc.'s total revenue was $1.43 M,
a decrease of 79.81% from the previous year.
In 2023, Perspective Therapeutics, Inc.'s net income was -$46.51 M.
See Perspective Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
| Operating Revenue |
$1.43 M |
$7.10 M |
$10.80 M |
$10.05 M |
$9.68 M |
$7.31 M |
$5.92 M |
$4.76 M |
$4.77 M |
$4.61 M |
| Cost of Revenue |
$0.00
|
$5.47 M
|
$6.18 M
|
$4.93 M
|
$4.56 M
|
$4.27 M
|
$4.08 M
|
$3.92 M
|
$4.64 M
|
$4.44 M
|
| Gross Profit |
$1.43 M
|
$1.63 M
|
$4.62 M
|
$5.12 M
|
$5.12 M
|
$3.05 M
|
$1.84 M
|
$838,000.00
|
$129,154.00
|
$167,393.00
|
| Gross Profit Ratio |
1
|
0.23
|
0.43
|
0.51
|
0.53
|
0.42
|
0.31
|
0.18
|
0.03
|
0.04
|
| Research and Development Expenses |
$21.31 M
|
$2.60 M
|
$2.58 M
|
$1.43 M
|
$1.13 M
|
$1.47 M
|
$1.75 M
|
$965,000.00
|
$528,049.00
|
$614,771.00
|
| General & Administrative Expenses |
$20.97 M
|
$10.87 M
|
$6.62 M
|
$4.69 M
|
$4.57 M
|
$4.17 M
|
$4.17 M
|
$3.92 M
|
$3.79 M
|
$2.40 M
|
| Selling & Marketing Expenses |
$97,000.00
|
$3.23 M
|
$2.80 M
|
$2.44 M
|
$2.98 M
|
$2.68 M
|
$2.66 M
|
$2.31 M
|
$1.35 M
|
$1.49 M
|
| Selling, General & Administrative Expenses |
$21.06 M
|
$14.21 M
|
$9.43 M
|
$7.13 M
|
$7.55 M
|
$6.85 M
|
$6.83 M
|
$6.23 M
|
$5.14 M
|
$3.89 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$73,000.00
|
$2,000.00
|
$0.00
|
-$48,000.00
|
-$456,284.00
|
$0.00
|
| Operating Expenses |
$42.38 M
|
$17.43 M
|
$12.01 M
|
$8.56 M
|
$8.60 M
|
$8.33 M
|
$8.57 M
|
$7.15 M
|
$5.21 M
|
$4.50 M
|
| Cost And Expenses |
$42.38 M
|
$22.90 M
|
$18.19 M
|
$13.49 M
|
$13.16 M
|
$12.59 M
|
$12.65 M
|
$11.07 M
|
$9.85 M
|
$8.94 M
|
| Interest Income |
$934,000.00
|
$1.12 M
|
$119,000.00
|
$59,000.00
|
$30,000.00
|
$108,000.00
|
$29,000.00
|
$118,000.00
|
$218,145.00
|
$282,745.00
|
| Interest Expense |
$84,000.00
|
$0.00
|
$119,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$950.00
|
$2,214.00
|
| Depreciation & Amortization |
$981,000.00
|
$344,000.00
|
$248,000.00
|
$9,000.00
|
$147,000.00
|
-$24,000.00
|
$80,000.00
|
$68,000.00
|
$470,851.00
|
$576,380.00
|
| EBITDA |
-$39.96 M |
-$14.84 M |
-$7.39 M |
-$3.43 M |
-$3.48 M |
-$5.30 M |
-$6.70 M |
-$6.19 M |
-$4.39 M |
-$4.05 M |
| EBITDA Ratio |
-27.87
|
-2.09
|
-0.68
|
-0.34
|
-0.36
|
-0.72
|
-1.13
|
-1.3
|
-0.92
|
-0.88
|
| Operating Income Ratio |
-28.55
|
-2.14
|
-0.68
|
-0.34
|
-0.36
|
-0.72
|
-1.14
|
-1.32
|
-1.07
|
-0.94
|
| Total Other Income/Expenses Net |
$835,000.00
|
$512,000.00
|
$119,000.00
|
$50,000.00
|
$30,000.00
|
$134,000.00
|
$29,000.00
|
$27,000.00
|
$154,000.00
|
$374,605.00
|
| Income Before Tax |
-$40.11 M
|
-$14.67 M
|
-$7.27 M
|
-$3.39 M
|
-$3.45 M
|
-$5.14 M
|
-$6.70 M
|
-$6.16 M
|
-$4.71 M
|
-$3.68 M
|
| Income Before Tax Ratio |
-27.97
|
-2.07
|
-0.67
|
-0.34
|
-0.36
|
-0.7
|
-1.13
|
-1.29
|
-0.99
|
-0.8
|
| Income Tax Expense |
-$2.65 M
|
$0.00
|
-$119,000.00
|
-$199,000.00
|
-$177,000.00
|
-$294,000.00
|
-$29,000.00
|
-$145,000.00
|
-$371,195.00
|
-$655,136.00
|
| Net Income |
-$46.51 M
|
-$14.67 M
|
-$7.15 M
|
-$3.19 M
|
-$3.27 M
|
-$4.85 M
|
-$6.70 M
|
-$6.16 M
|
-$4.71 M
|
-$3.68 M
|
| Net Income Ratio |
-32.43
|
-2.07
|
-0.66
|
-0.32
|
-0.34
|
-0.66
|
-1.13
|
-1.29
|
-0.99
|
-0.8
|
| EPS |
-1.4 |
-0.1 |
-0.0504 |
-0.0307 |
-0.0484 |
-0.0723 |
-0.12 |
-0.11 |
-0.0856 |
-0.0671 |
| EPS Diluted |
-1.4 |
-0.1 |
-0.0504 |
-0.0307 |
-0.0484 |
-0.0723 |
-0.12 |
-0.11 |
-0.0856 |
-0.0671 |
| Weighted Average Shares Out |
$26.76 M
|
$142.10 M
|
$141.99 M
|
$103.84 M
|
$67.60 M
|
$67.04 M
|
$55.16 M
|
$55.02 M
|
$55.01 M
|
$54.88 M
|
| Weighted Average Shares Out Diluted |
$26.76 M
|
$142.10 M
|
$141.99 M
|
$103.84 M
|
$67.60 M
|
$67.04 M
|
$55.16 M
|
$55.02 M
|
$55.02 M
|
$54.88 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
